JP Patent

JP6426778B2 — シチジン類似体の経口製剤およびその使用方法

Assigned to Celgene Corp · Expires 2018-11-21 · 7y expired

What this patent protects

Patent listed against Vidaza.

Drugs covered by this patent

Patent Metadata

Patent number
JP6426778B2
Jurisdiction
JP
Classification
—
Expires
2018-11-21
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.